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methods

Study design and setting
Mali is a landlocked West African country with a size of 1,241,248 km 2 and population of approximately 14.5 million people in 2009. [6] Bamako, the capital city, has a population of approximately two million people and is divided into six urban districts, with each district having a health referral center, where TB diagnostic and treatment services are available. The University Teaching Hospital (UTH) at Point-G is located in district three and serves as the last level of reference for TB. In 2014, more than one-third of the total TB patients in Mali were managed in Bamako. In addition, 80% of the Malian MDR-TB cases were included in this study. [7] Since 2006, SEREFO BSL-3 laboratory, yearly certified, within the University Clinical Research Center (UCRC) of the University of Sciences, Techniques and Technologies of Bamako (USTTB) is performing TB culture, drug susceptibility testing (DST), and strain typing. The suspected pulmonary TB patients were enrolled from local reference centers and the UTH at Point-G in Bamako, Mali. Mycobacterial isolates from patients had been freeze. In the present cross-sectional analysis, we focused on baseline strains and their drug susceptibility profiles.
Study population
Suspected TB patients were screened at the study sites based on smear-positive result of either Ziehl-Neelsen (ZN) or auramine/rhodamine (A/R) staining, and consented participants were then enrolled into the studies. Only TB patients with Mycobacterium tuberculosis complex (MTBc) infection confirmed by culture and strain-typed (to determine subspecies) during the 10-year study period were included in the final analysis.
Patients were classified based on their TB treatment history as new patients, who had received TB treatment for the first time for <4 weeks and previously treated patients, who had received TB treatment for >4 weeks according to the WHO guidelines. Patients received treatment through their physicians in accordance with national guidelines of the national TB program in Mali. [8] Newly, TB diagnosed patients are treated with a fixed dose combination of 2 months of rifampicin (R), isoniazid (H), pyrazinamide (Z), and ethambutol (E) and 4 months of (R) and (H) (2RHZE/4RH; Cat. 1) while retreatment patients received 2 months of (R), (H), (Z), (E), and streptomycin (S), followed by 1 month with the same combination but without (S) and 5 months of (R), (H), and (E) (2RHZES/1RHZE/5RHE; Cat. 2). Patients clinically suspected of having MDR disease (those who failed Cat. 2 regimen) or confirmed MDR-TB patients underwent a 6-month course of kanamycin (K), ofloxacin (O), ethionamide (Et), and (Z) during the 6-month inpatient period and followed by 15 months of the same combination without kanamycin (6KOEtZ/15OEtZ). [8] Although approved by the WHO, Mali has not yet started implementation of the short-course 9-month MDR regimen.
Laboratory tests
Preenrollment sputum smear microscopy by ZN or fluorescent smear microscopy using A/R (fluorescent microscopy [FM]) at local reference centers was followed by indirect FM and culture at the UCRC-SEREFO BSL-3 laboratory. This TB laboratory is certified by the College of American Pathologists for external quality control. Confirmed MTBc isolates underwent DST and spoligotyping.
Culture and drug susceptibility testing
Sputum specimens were digested and decontaminated using the standard N-Acetyl-L-Cysteine/4% NaOH solution, concentrated by centrifugation (4500 rpm), and inoculated on both liquid (Mycobacterium Growth Incubator Tube [BBL™ MGIT™ Becton Dickinson, Sparks MD, USA]), and solid (Middlebrook 7H11 Agar and Selective 7H11 Agar) media. Simultaneously, an aliquot of concentrated specimen was prepared for indirect commercial A/R staining (BBL™ Becton Dickinson, Sparks MD, USA). Speciation of positive mycobacterial cultures was based on acid-fast bacilli positivity in FM and colony morphology on solid medium and was confirmed by nucleic acid probes (AccuProbe ® GenProbe, San Diego, CA, USA). Indirect first-line DST was performed on MTBc isolates using MGIT AST/SIRE System (Becton Dickinson, Sparks, MD, USA), and the results were interpreted based on the United States of America (USA) Center for Disease Control (CDC) recommendations for critical drug concentrations. [9] Moreover, second-line DST was performed on randomly selected MDR isolates at collaborating centers.
Spoligotyping
Spoligotyping was performed using a commercially available kit (Isogen Life Science, Netherlands). [10] Strain comparisons were made with SPOTCLUST (SpolDB3-based) database following the development of the film. Corresponding shared spoligotypes were further defined using the SITVIT (Institut Pasteur de la Guadeloupe) database.
Data and statistical analysis
A descriptive analysis was conducted to determine the median of age with the minimum and maximum age. The proportion of each strain type and their drug susceptibility profiles was calculated. Analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC, USA) and Epi Info September 2002's version 7 (CDC, Atlanta, USA).
Results
Sociodemographic characteristics
Of the 445 participants, the median age was 31 years (range 3-78), 104 (23.4%) were women, and 48 (10.8%) were Table 1 and Figure 1 ]. The other subspecies were all below 5% of prevalence except M. tuberculosis family 33, which represented 6.7%
[ Table 1 and Figure 1 ]. For lineage distribution, of 445 isolates identified, 4 strains belonged to M. bovis and the remaining 441 were distributed between the major six mycobacterial lineages. Specifically, 301 (68.2%) belonged to the modern Table 2 and Figure 1 ].
Prevalence of spoligotype during the past 10 years of follow-up
Although three subspecies dominated during the 10 years of follow-up, we also noticed the appearance of other spoligotypes during the past 5 years (2011-2016) such as MTB H37Rv, MTB Haarlem, MTB family 33, and MTB X families [ Table 1 ].
Drug susceptibility and strain type
Among the 349 (78.4%) isolates tested for TB, first-and second-line DST, 209 (59.9%) were pan sensitive to all drugs tested, and 140 (40.1%) were resistant to at least one drug [ Table 3 ]. The prevalence of MDR-TB was 3.3% and 67.3%, respectively, in patients naive to treatment and previously treated patients [ Table 3 ]. Of the three major families, the proportion of MDR-TB was higher in MTB T1 family with 54 (47.4%) [ Table 4 ], and moreover, the two extensively drug resistance-TB isolates belonged to the MTB T clade [ Table 4 ]. Despite its low number, MTB H37Rv showed a high proportion of MDR strain on 8 (72.7%) [ Table 4 ]. Contd...
dIscussIon
Lineage 4 and lineage 6 were the dominant causes of TB in Bamako region during the past 10 years, with, respectively, 68.2% and 16.8% of the cases. Recent genetic characterization of M. tuberculosis strains has greatly facilitated and improved understanding of the molecular epidemiology of TB. [10] Spoligotyping appears to have the specific characteristics needed to address both a rapid mycobacterial identification and strain tracking of infections (molecular epidemiology) including investigation of chains of transmission. In fact, this technique is very helpful and allows the concomitant identification and differentiation of M. tuberculosis strains and save time needed to culture as slow-growing bacterium such as M. tuberculosis. [5, 10] The clinical utility of spoligotyping is also potentialized by its rapidity in bacterial identification and comparison of strain molecular profiles, which is very useful in surveillance of TB transmission and prevention of further spread of the disease. Although some studies pointed out that spoligotyping technique has low discriminatory value to differentiate between two strains (for chain of transmission investigations), however identifications of MTBc subspecies by spoligotyping (which this study is about) and its comparability to other available techniques like mycobacterial interspersed repetitive units-variable number of tandem repeats (MIRU-VNTR), is greatly recognized. [11, 12] We followed using spoligotyping the distribution of mycobacterial strains isolated from TB patients in Bamako urban region during the past 10 years. Although we noticed that few patients have traveled to Bamako city to receive better care, we have to mention that all were recruited in this region. We observed a high proportion of the three subspecies (MTB T1, MAF 2 and MTB LAM), similarly to what Traore et al. reported in 2012, [3, 13] suggesting a relative stability and endemicity of the disease transmission. However, unlike Mali, the continuous predominance of MTB T1 was not observed in our neighboring countries such as Burkina Faso, Benin, and Nigeria. Gehre et al. in 2016 reported an equally distribution of polyphyletic T1 across West African countries, but was not the predominant one in most of these countries . [14] Beyond our West African region, MTB LAM or MTB Cameroon was consistently reported to be the most frequent in Cameroun. [4, [15] [16] [17] We found eight (1.8%) strains of MTB Beijing with a slight increased proportion compared to Traore et al.'s report of 2012 (1.6%) [3] while a higher prevalence of 10.3% was reported in Benin. [15] The Beijing strain was first described in 2010 in Bamako and continued to be a challenge in our region and globally because of its usual higher resistance to TB drugs. [17, 18] Our study identified 25 spoligotypes during the past 10 years while only 20 were reported from 2006 to 2010. [3] A total of four new isolates, namely, MTB T3, MTB Haarlem 2, MTB EAI3, and MTB family 33 were seen during the past 5 years of follow-up. The reasons of this continuous increase in infecting strains' diversity are not yet clear and require further investigations. Some factors could be involved including people mobility across countries, changes in strains' fitness, and host and/or environmental factors.
It has to be noted that 140 isolates (40.1%) were resistant to at least one TB first-line drug, and the global prevalence of MDR-TB was 3.3% and 67.3%, respectively, in patients naive to treatment and previously treated patients. This seems to be high and is in line with the global increase of primary DR in Mali. [19] In a separate study, 2.9% of newly infected TB patients had resistance to rifampicin after screened by Xpert MTB/RIF. [20] This rate should be taken seriously by the Mali National TB Program to plan further actions to avoid uncontrolled spread of drug-resistant strains in the country.
The number of patients included in this study may not be extrapolated to the whole country as 10,000 new TB cases are detected yearly in Mali with a third in Bamako region where this study was conducted. Despite this limitation, this study is unique in Mali and/or African region in that it collected and identified continuously mycobacterial strains over 10-year period. These data could be used to predict the disease transmission dynamics in the region and to propose a more adapted and effective public health response in the future.
conclusIon Genotyping of M. tuberculosis strains in Mali showed a high genetic diversity during the past 10 years. M. tuberculosis T1 strain within modern lineage Euro-American was the most prevalent. The continuous leading proportion of these strains within M. tuberculosis complex during the past 10 years may suggest a stable and conserved host-pathogen interaction. A targeted intervention is thus necessary to overcome this endemic disease in the region.
